See more : GreenX Metals Limited (PDZ.L) Income Statement Analysis – Financial Results
Complete financial analysis of EirGenix Inc. (6589.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EirGenix Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nath Bio-Genes (India) Limited (NATHBIOGEN.BO) Income Statement Analysis – Financial Results
- hmvod Limited (8103.HK) Income Statement Analysis – Financial Results
- XPhyto Therapeutics Corp. (4XT.DE) Income Statement Analysis – Financial Results
- Impellam Group plc (IGPPF) Income Statement Analysis – Financial Results
- MEDIASEEK,inc. (4824.T) Income Statement Analysis – Financial Results
EirGenix Inc. (6589.TWO)
About EirGenix Inc.
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. EirGenix Inc. was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.02B | 1.48B | 1.70B | 1.07B | 476.09M |
| Cost of Revenue | 785.91M | 724.57M | 604.31M | 321.17M | 221.42M |
| Gross Profit | 236.74M | 756.45M | 1.09B | 750.67M | 254.67M |
| Gross Profit Ratio | 23.15% | 51.08% | 64.40% | 70.04% | 53.49% |
| Research & Development | 952.30M | 800.14M | 893.51M | 1.56B | 963.09M |
| General & Administrative | 254.20M | 236.68M | 223.56M | 148.30M | 117.72M |
| Selling & Marketing | 62.23M | 50.84M | 33.60M | 26.65M | 25.00M |
| SG&A | 316.43M | 287.52M | 257.17M | 174.95M | 142.73M |
| Other Expenses | -11.00K | 166.56M | 27.93M | -29.91M | -3.48M |
| Operating Expenses | 1.27B | 1.09B | 1.15B | 1.74B | 1.10B |
| Cost & Expenses | 2.05B | 1.81B | 1.75B | 2.06B | 1.32B |
| Interest Income | 134.47M | 59.58M | 10.37M | 3.09M | 2.27M |
| Interest Expense | 10.40M | 9.64M | 21.15M | 28.50M | 18.53M |
| Depreciation & Amortization | 238.84M | 205.28M | 185.00M | 172.15M | 93.70M |
| EBITDA | -664.41M | 100.61M | 164.98M | -840.67M | -728.75M |
| EBITDA Ratio | -64.97% | 6.77% | 9.76% | -78.43% | -158.37% |
| Operating Income | -1.03B | -105.07M | -19.33M | -1.01B | -847.67M |
| Operating Income Ratio | -100.91% | -7.09% | -1.14% | -94.49% | -178.05% |
| Total Other Income/Expenses | 118.33M | 216.50M | -21.84M | -55.32M | -13.25M |
| Income Before Tax | -913.65M | -114.32M | -41.17M | -1.04B | -860.93M |
| Income Before Tax Ratio | -89.34% | -7.72% | -2.43% | -97.15% | -180.83% |
| Income Tax Expense | 1.56M | 1.23M | 1.42M | 347.00K | 0.00 |
| Net Income | -915.21M | -115.54M | -42.58M | -1.04B | -860.93M |
| Net Income Ratio | -89.49% | -7.80% | -2.51% | -97.19% | -180.83% |
| EPS | -3.00 | -0.38 | -0.18 | -5.15 | -5.39 |
| EPS Diluted | -3.00 | -0.38 | -0.18 | -5.15 | -5.39 |
| Weighted Avg Shares Out | 304.89M | 303.26M | 242.66M | 202.25M | 159.63M |
| Weighted Avg Shares Out (Dil) | 304.89M | 303.26M | 242.66M | 202.25M | 159.63M |
Source: https://incomestatements.info
Category: Stock Reports